Javascript must be enabled to continue!
Effect of the ganglioside GM1, on cerebral metabolism, microcirculation, recovery kinetics of ECoG and histology, during the recovery period following focal ischemia in cats.
View through CrossRef
The effect of the ganglioside GM1 on the recovery of local cerebral glucose metabolism (lCMRgl), recovery kinetics of cerebrocortical electrical activity, cerebral blood flow and redox state as well as histological changes following focal ischemia has been studied in the cat. Ischemia was produced by occlusion of the left middle cerebral artery (MCA), and GM1 (30 mg/kg) was injected intravenously at 30 min after the MCA occlusion or at the time of release of the occlusion, at 120 min. Another group of animals were subjected to the same ischemic insult, but without GM1 treatment, and sham-operated treated and not treated cats were also studied. The animals of both GM1-treated and non-treated stroke groups were classified into 2 groups (severe and moderate) depending on the depression of electrocortical activity in the ischemic hemisphere at 30 min of the ischemia. There was a significant increase in local cerebral blood flow in the ischemic area in the treated animals. Additionally there was a significant treatment effect on the left peripheral MCA territory for lCMRgl in the 30 min treated moderate group, (p less than .05). This group of animals showed decreased lCMRgl accompanied by less severe histological damage suggesting that GM1 may produce metabolic depression so as to maintain a normal flow-metabolism couple and prevent ischemic structural damage. The possible mechanism of metabolic depression induced by GM1 is briefly discussed.
Ovid Technologies (Wolters Kluwer Health)
Title: Effect of the ganglioside GM1, on cerebral metabolism, microcirculation, recovery kinetics of ECoG and histology, during the recovery period following focal ischemia in cats.
Description:
The effect of the ganglioside GM1 on the recovery of local cerebral glucose metabolism (lCMRgl), recovery kinetics of cerebrocortical electrical activity, cerebral blood flow and redox state as well as histological changes following focal ischemia has been studied in the cat.
Ischemia was produced by occlusion of the left middle cerebral artery (MCA), and GM1 (30 mg/kg) was injected intravenously at 30 min after the MCA occlusion or at the time of release of the occlusion, at 120 min.
Another group of animals were subjected to the same ischemic insult, but without GM1 treatment, and sham-operated treated and not treated cats were also studied.
The animals of both GM1-treated and non-treated stroke groups were classified into 2 groups (severe and moderate) depending on the depression of electrocortical activity in the ischemic hemisphere at 30 min of the ischemia.
There was a significant increase in local cerebral blood flow in the ischemic area in the treated animals.
Additionally there was a significant treatment effect on the left peripheral MCA territory for lCMRgl in the 30 min treated moderate group, (p less than .
05).
This group of animals showed decreased lCMRgl accompanied by less severe histological damage suggesting that GM1 may produce metabolic depression so as to maintain a normal flow-metabolism couple and prevent ischemic structural damage.
The possible mechanism of metabolic depression induced by GM1 is briefly discussed.
Related Results
Effect of GM1 ganglioside after focal cerebral ischemia in halothane-anesthetized cats.
Effect of GM1 ganglioside after focal cerebral ischemia in halothane-anesthetized cats.
The effect of the ganglioside GM1 was studied in a focal cerebral ischemia model in 30 cats consisting of 2 hours of middle cerebral artery occlusion followed by 4 hours of recircu...
Effects of cyclodextrins on GM1-gangliosides in fibroblasts from GM1-gangliosidosis patients
Effects of cyclodextrins on GM1-gangliosides in fibroblasts from GM1-gangliosidosis patients
Abstract
Objectives
GM1-gangliosidosis is an inherited disorder characterized by the accumulation of GM1-gangliosides in many ti...
Functional incorporation of ganglioside into intact cells: induction of choleragen responsiveness.
Functional incorporation of ganglioside into intact cells: induction of choleragen responsiveness.
NCTC 2071 cells are unable to synthesize the monosialoganglioside GM1. When grown in chemically defined medium these cells contained no detectable GM1 and did not accumulate 3': 5'...
Choleragen-mediated release of trapped glucose from liposomes containing ganglioside GM1.
Choleragen-mediated release of trapped glucose from liposomes containing ganglioside GM1.
125I-Labeled choleragen was bound to liposomes containing galactosyl-N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide (GM1), but not in large amounts to gangl...
Regulation of Transmembrane Signaling by Ganglioside GM1 :
Regulation of Transmembrane Signaling by Ganglioside GM1 :
Abstract : Interaction of antibodies to ganglioside GM1 with Neuro2a
cells was studied to investigate the role of GM1 in cell signaling. Binding of
anti‐GM1 to Neuro2a cells in...
Human IgM monoclonal proteins that bind 3-fucosyllactosamine, asialo-GM1, and GM1.
Human IgM monoclonal proteins that bind 3-fucosyllactosamine, asialo-GM1, and GM1.
Abstract
Analysis of monoclonal human Ig that occur in association with lymphoproliferative diseases has provided valuable information about antibody structure and i...
Effects of simulated ischemia-reperfusion and atorvastatin on INa in rat left ventricular myocytes.
Effects of simulated ischemia-reperfusion and atorvastatin on INa in rat left ventricular myocytes.
Objective
To observe time dependent effects of simulated ischemia-reperfusion on transient sodium currents (INa) in rat left ventricular myocytes, and effects of ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

